<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761501</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00001</org_study_id>
    <nct_id>NCT00761501</nct_id>
  </id_info>
  <brief_title>Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E</brief_title>
  <official_title>Phase I, Open-label, Randomized, 3-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the uptake in the body of naproxen; one of the two
      active substances in PN400. We also want to show that the body's uptake of naproxen given as
      PN400 is comparable to that of currently marketed naproxen tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>pre-dose and multiple times post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN400</intervention_name>
    <description>Oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>VIMOVOâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen (Proxen S)</intervention_name>
    <description>Oral</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Proxen S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen (Naprosyn E)</intervention_name>
    <description>Oral</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Naprosyn E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of greater than or equal to 19 to less than or equal to 30 kg/m2
             and weight of greater than or equal to 50 to less than or equal to 100 kg

          -  Clinically normal physical exams and laboratory measurements

        Exclusion Criteria:

          -  Subject has received another investigational drug within 4 weeks preceding this study
             or planning to participate in another study at any time during the period of this
             study

          -  Any significant medical or psychiatric condition that could affect the interpretation
             of the PK data, or which otherwise would contraindicate participation in a clinical
             trial

          -  Any GI disease, abnormality or gastric surgery that may interfere with gastric
             emptying, motility and drug absorption

          -  Subject who has donated a unit of blood or plasma within 3 months prior to the
             Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aslak Rautio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Hermelinen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kuhn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase I Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark Sostek, MD, Medical Science Director, Development Projects</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

